

Minneapolis VA Health Care System
IBC (Institutional Biosafety Committee)

MEETING MINUTES

November 23, 2021

Zoom

The meeting was called to order on November 23, 2021 at 5:00 PM and a quorum was present.

ATTENDANCE

Voting Members Present:

██████████	Community Member
██████████	Infectious Disease Physician
██████████	Attending Veterinarian
██████████	Vice Chair
██████████	Community Member
██████████	Chair

Non-Voting Attendees, Staff and Guests Present:

Recording:

██████████	Staff
------------	-------

ITEMS

1 Welcome and Opening Remarks

2 Continuing Reviews

2.1 [██████████] Orexin and serotonin interactions to promote physical activity and prevent obesity

PI:	Catherine Kotz
Reference Number:	██████████
Sponsor:	Department of Veterans Affairs
Submission Type:	Continuing Review/Progress Report

Review Type:	Full Committee Review
Action:	Approved

Effective Date: November 23, 2021
Project Status: Active
Vote: Total = 6; For = 6; Opposed = 0; Abstained = 0;
Primary Reviewer: [REDACTED]

Discussion and Remarks:

No changes to IBC approved protocols are noted in this continuing review. Also there were no problems in the carrying out of the approved protocols during the past year.

2.2 [REDACTED] **Pharmacogenetic control of physical activity and food intake**

PI: Catherine Kotz
Reference Number: [REDACTED]
Submission Type: Continuing Review/Progress Report

Review Type: Full Committee Review
Action: Approved
Effective Date: November 23, 2021
Project Status: Active
Vote: Total = 6; For = 6; Opposed = 0; Abstained = 0;
Primary Reviewer: [REDACTED]

Discussion and Remarks:

There have been no changes to IBC approved protocols for this study as indicated by the PI in this continuing review. No problems in carrying out these protocols are noted.

2.3 [REDACTED] **Impairment and recovery of CD4 T cell-dependent B cell responses after sepsis**

PI: Thomas Griffith, Ph.D.
Reference Number: [REDACTED]
Submission Type: Continuing Review/Progress Report

Review Type: Full Committee Review
Action: Approved
Effective Date: November 23, 2021
Project Status: Active
Vote: Total = 6; For = 6; Opposed = 0; Abstained = 0;
Primary Reviewer: [REDACTED]

Discussion and Remarks:

In this continuing review there were no changes made to laboratory protocols. There was a change in personnel noted and all training of personnel is up to date. There were no problems noted in these protocols and laboratory inspection is current.

2.4 [REDACTED] **Combinatorial Targeting of the Cell Cycle and Key Interacting Pathways in Mesothelioma**

PI: Mark Klein
Reference Number: [REDACTED]
Sponsor: VA-ORD Biomedical Laboratory Research & Development
Submission Type: Continuing Review/Progress Report

Review Type: Full Committee Review
Action: Approved
Effective Date: November 23, 2021
Project Status: Active
Vote: Total = 6; For = 6; Opposed = 0; Abstained = 0;
Primary Reviewer: [REDACTED]

Discussion and Remarks:

In this continuing review there have been no changes to the IBC approved protocols for this study, nor have there been any problems with carrying out these protocols.

2.5 [REDACTED] **Precision Oncology-Based Therapeutic Targeting in Mesothelioma**

PI: Mark Klein
Reference Number: [REDACTED]
Sponsor: Department of Defense
Submission Type: Continuing Review/Progress Report

Review Type: Full Committee Review
Action: Approved
Effective Date: November 23, 2021
Project Status: Active
Vote: Total = 6; For = 6; Opposed = 0; Abstained = 0;
Primary Reviewer: [REDACTED]

Discussion and Remarks:

There have been no changes in the study of protocols approved by the IBC. In addition, no problems were reported in carrying out IBC approved protocols in the past year.

2.6 [REDACTED] **Novel Plant Alkaloids for the Treatment of Obesity in Mice**

PI: Patricia Bunney
Reference Number: [REDACTED]
Submission Type: Continuing Review/Progress Report

Review Type: Full Committee Review
Action: Modifications Required
Effective Date: November 23, 2021
Project Status: Active
Vote: Total = 6; For = 6; Opposed = 0; Abstained = 0;

Primary Reviewer: [REDACTED]

Discussion and Remarks:

The Continuing Review of this protocol indicates that there are no changes to the IBC approved protocol and that there have been no problems in carrying out the study. However, Section IV - Recombinant DNA of the RPSS should be revised to indicate "No" to question 2, with respect to limitation of project to propagation of short DNA sequences, and Section IV.2.b.3 of the RPSS should be completed. After modification of RPSS, approval will be by Designated Member Review.

3 Closures

3.1 [REDACTED] Cyclin D1 and CDK2 in hepatocyte proliferation

PI: Mark Klein, M.D.

Reference Number: [REDACTED]

Sponsor: Randy Shaver Cancer Research and Community Fund, NIH/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Submission Type: Closure/Final Report

Review Type: Full Committee Review

Action: Closed

Effective Date: November 23, 2021

Vote: Total = 6; For = 6; Opposed = 0; Abstained = 0;

Primary Reviewer: [REDACTED]

Discussion and Remarks:

This study of Dr Klein's has been closed. Laboratory work is completed, and no previous problems noted.

4 Adjourn

The meeting adjourned on November 23, 2021 at 5:15 PM.

[REDACTED]